[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kazakhstan Scientific Society for Study of intestine diseases\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100556326",false,"NCT06523647","Clinical Efficacy of Ustekinumab in Crohn's Disease","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components","Inclusion Criteria:\n\n* Patients aged 18 years and older;\n* Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024\n* Patients who provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindications to the use of the drug Ustekinumab per the current instructions:\n\n  * Clinically significant active infection (active tuberculosis, active viral hepatitis);\n  * Pregnancy and lactation;\n  * A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen;\n  * Ulcerative colitis;\n  * Malignant gastrointestinal diseases in history or at the time of inclusion in the study;\n  * Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus;\n  * Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient);\n* Participation in an interventional clinical trial.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","OBSERVATIONAL","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components.",[23],"Crohn's Disease","RECRUITING","2024-07-23",{"date":27,"type":28},"2024-07-26","ACTUAL",{"date":30,"type":28},"2023-06-27",{"date":32,"type":19},"2025-12",{"name":34,"class":35},"Kazakhstan Scientific Society for Study of intestine diseases","OTHER",4,{"id":38,"slug":4,"hasResults":10,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":43,"enrollmentInfo":44,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":41,"conditions":46,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":57},"100555794","NCT06516718","An Assessment of the Effectiveness (Efficacy) of Odeston (Odeston®) in Patients With Chronic Cholecystitis in Real Medical Practice","Post-marketing Observational Clinical Study: Assessment of the Effectiveness (Efficacy) of Odeston (Odeston®) in Patients With Chronic Cholecystitis in Real Medical Practice","Inclusion Criteria:\n\n* Men and women aged 18 to 65 years;\n* BMI 18.5 - 40;\n* Verified diagnosis: chronic acalculous cholecystitis;\n* Voluntary desire to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n* Presence of stones in the gall bladder and bile ducts;\n* The presence of jaundice, cholestatic liver diseases, liver cirrhosis with decompensation;\n* Increased ALT, AST above the 3 upper limits of normal;\n* Hypersensitivity to the components of the drug Odeston;\n* Pregnancy and lactation;\n* Prolonged fasting and total parenteral nutrition;\n* Patients with symptoms of acute abdomen at the time of inclusion in the study;\n* Patients with symptoms of acute neurological pathology at the time of inclusion in the study and\u002For аcute cerebrovascular accident, a history of convulsive syndrome;\n* Presence of cancer;\n* Acute infectious diseases at the time of inclusion in the study;\n* Fever of any origin (above 37.5 C);\n* Patients with symptoms of heart failure;\n* Patients with symptoms of pulmonary failure;\n* Patients with symptoms of acute or chronic renal failure;\n* A decompensated form of diabetes;\n* Patients with signs of psychiatric disorders.","65 Years",{"count":45,"type":19},169,[47],"Chronic Cholecystitis","NOT_YET_RECRUITING","2024-07-17",{"date":51,"type":28},"2024-07-24",{"date":53,"type":19},"2024-08",{"date":55,"type":19},"2025-08",{"name":34,"class":35},15,""]